Overview

* Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations

* Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement

* Company extends cash runway into Q3 2027, supporting EDIT-401 progression

Outlook

* Editas plans to submit IND/CTA for EDIT-401 by mid-2026

* Company aims for initial human proof-of-concept data for EDIT-401 by end-2026

* Editas extends cash runway into Q3 2027, supporting EDIT-401 progression

Result Drivers

* BMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreement

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $7.50

Collabor mln

ation

and

other

research

and

developm

ent

revenue

Q3 EPS -$0.28

Q3 Net Beat -$25.12 -$28.10

Income mln mln (11

Analysts

)

Q3 Basic -$0.28

EPS

Q3 $32.09

Operatin mln

g

Expenses

Q3 -$24.55

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

* Wall Street's median 12-month price target for Editas Medicine Inc ( EDIT ) is $4.00, about 38.2% above its November 7 closing price of $2.47

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)